Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

Gilead, Multi-Target Antibody Collaboration

More Like This

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023